Earnings ·
Collegium Pharmaceutical reported second quarter 2026 financial results, generating quarterly net revenues of $199.9…
COLLCollegium Pharmaceutical, Inc
Collegium Pharmaceutical reported second quarter 2026 financial results, generating quarterly net revenues of $199.9 million, a 6% increase year-over-year. JORNAY PM revenue rose 41% to $46.1 million, while the pain portfolio declined 9% to $140.9 million due to lower Nucynta franchise revenues. The company completed its acquisition of AZSTARYS in May, contributing $12.9 million in partial quarter sales. Collegium updated its full-year 2026 guidance, lowering product revenue net expectations to $825–$855 million and adjusted EBITDA to $445–$470 million, while raising AZSTARYS revenue estimates to $65–$75 million. The company operates in the biopharmaceutical industry, developing and commercializing medicines for central nervous system and pain conditions.